Publication
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
Journal Paper/Review - Feb 9, 2022
Perrig Kathrin, Krupka Niklas, Jordi Sebastian Bruno Ulrich, Rossel Jean-Benoit, Biedermann Luc, Greuter Thomas, Schreiner Philipp, Vavricka Stephan R, Juillerat Pascal, Burri Emanuel, Zimmermann Dorothee, Maillard Michel H, Sulz Michael Christian, Brand Stephan, Rogler Gerhard, Misselwitz Benjamin
Units
PubMed
Doi
Contact
Citation
Type
Journal
Publication Date
Issn Print
Pages
Brief description/objective
Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This study aims to summarize the experience of golimumab in a real-world setting in Switzerland.